Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL - PubMed (original) (raw)
. 1998 Mar;16(11):1383-90.
doi: 10.1038/sj.onc.1201664.
Affiliations
- PMID: 9525737
- DOI: 10.1038/sj.onc.1201664
Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL
G P Amarante-Mendes et al. Oncogene. 1998 Mar.
Abstract
Bcr - Abl is the molecule responsible for both the transformation phenotype and the resistance to chemotherapeutic drugs found in chronic myelogenous leukemia (CML) cells. Wild-type HL-60, a transformed pro-myelocytic cell line, is very susceptible to apoptosis-inducing agents. We show here that expression of Bcr - Abl in HL-60 cells rendered them extremely resistant to apoptosis induced by a wide variety of agents. The anti-apoptotic effect of Bcr - Abl was found to be independent of the phase of the cell cycle. Treatment with antisense oligonucleotides directed to bcr decreased the expression of the ectopic bcr - abl and restored susceptibility to apoptosis. Double mutations affecting the autophosphorylation site and the phosphotyrosine-binding motif (FLVRES) have been previously shown to impair the transforming activity of Bcr - Abl in fibroblasts and hematopoietic cells, however HL-60 cells expressing this double mutant molecule exhibited the same level of resistance to apoptosis as those expressing the wild-type Bcr - Abl. Interestingly, wild type and mutant Bcr - Abl induced in HL-60 cells a dramatic down regulation of Bcl-2 and increased the levels of Bcl-xL. The level of Bax did not change in response to the presence of Bcr - Abl. Antisense oligonucleotides targeted to bcl-x downregulated the expression of Bcl-x, and increased the susceptibility of HL-60. Bcr - Abl cells to staurosporine. Importantly, HL-60 cells overexpressing Bcl-xL showed higher expression of Bcl-xL but lower resistance to apoptosis when compared to HL-60. Bcr - Abl cells. The results described here show that Bcr - Abl is a powerful mammalian anti-apoptotic molecule and can act independently of Bcl-2. Bcl-xL, however, seems to participate in part in Bcr - Abl-mediated resistance to apoptosis in HL-60 cells.
Similar articles
- Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Shi X, et al. Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24. Clin Cancer Res. 2009. PMID: 19240172 - Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Hoover RR, et al. Oncogene. 2001 Sep 13;20(41):5826-35. doi: 10.1038/sj.onc.1204549. Oncogene. 2001. PMID: 11593388 - STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM. Greene LM, et al. J Pharmacol Exp Ther. 2007 Apr;321(1):288-97. doi: 10.1124/jpet.106.116640. Epub 2007 Jan 3. J Pharmacol Exp Ther. 2007. PMID: 17202400 - While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.
Farooqi AA, Nawaz A, Javed Z, Bhatti S, Ismail M. Farooqi AA, et al. Arch Immunol Ther Exp (Warsz). 2013 Feb;61(1):59-74. doi: 10.1007/s00005-012-0204-z. Epub 2012 Dec 11. Arch Immunol Ther Exp (Warsz). 2013. PMID: 23229677 Review. - BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
Cotter TG. Cotter TG. Leuk Lymphoma. 1995 Jul;18(3-4):231-6. doi: 10.3109/10428199509059612. Leuk Lymphoma. 1995. PMID: 8535187 Review.
Cited by
- Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.
Cuesta-Domínguez Á, Ortega M, Ormazábal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, Figuera Á, Arranz E, Vizmanos JL, Bueren JA, Río P, Fernández-Ruiz E. Cuesta-Domínguez Á, et al. PLoS One. 2012;7(2):e32451. doi: 10.1371/journal.pone.0032451. Epub 2012 Feb 27. PLoS One. 2012. PMID: 22384256 Free PMC article. - Active Akt and functional p53 modulate apoptosis in Abelson virus-transformed pre-B cells.
Gong L, Unnikrishnan I, Raghavan A, Parmar K, Rosenberg N. Gong L, et al. J Virol. 2004 Feb;78(4):1636-44. doi: 10.1128/jvi.78.4.1636-1644.2004. J Virol. 2004. PMID: 14747529 Free PMC article. - Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, Dou QP, Wang X, Liu J. Chen X, et al. Oncotarget. 2014 Oct 15;5(19):9118-32. doi: 10.18632/oncotarget.2361. Oncotarget. 2014. PMID: 25193854 Free PMC article. - Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, Chen W, Andreeff M. Carter BZ, et al. Blood. 2006 Feb 15;107(4):1555-63. doi: 10.1182/blood-2004-12-4704. Epub 2005 Oct 27. Blood. 2006. PMID: 16254145 Free PMC article. - Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Era T, Witte ON. Era T, et al. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1737-42. doi: 10.1073/pnas.97.4.1737. Proc Natl Acad Sci U S A. 2000. PMID: 10677527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous